Research teams typically report on how a compound performs across a full tested range rather than isolating one figure, since higher amounts are usually only meaningful when understood alongside the lower levels that came before them in the same study design
Tirzepatide, a newer GLP-1/GIP dual agonist, and retatrutide, a triple agonist still in trials, have pushed results even further, with average weight loss approaching 2025% of body weight
By contrast, Hone Health (4.9 stars, ~2% low) and SkinnyRx (4.6 stars, 5% low) were standouts in terms of customer satisfaction
It could be your general practice doctor or an internist, says Kessler
Unlike the standard Noom Weight plan, Noom Med includes clinical oversight from a care team and may prescribe medications like GLP-1s